Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Osteoarthritis

In brief

Tanezumab, administered for up to 1 1/2 years, reduces the pain of osteoarthritis without affecting how nerve impulses are transmitted in sensory nerves

Key facts

Study ID
NCT00960804
Run by
Pfizer
People needed
21
Starts
2010-02-15
Expected to finish
2010-11-11
Last updated by the study team
2021-02-08

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.